Search Results for: CTNNB1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel ACP1 acid phosphatase 1
  • Adenine
  • 4-Nitrophenyl Phosphate
Novel AJAP1 adherens junctions associated protein 1
Novel AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • Co-inhibition by CTLA4
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • KEAP1-NFE2L2 pathway
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Mitochondrial unfolded protein response (UPRmt)
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
Novel AMER1 APC membrane recruitment protein 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Neddylation
  • KEAP1-NFE2L2 pathway
  • Osteopathia striata with cranial sclerosis
Novel APC APC regulator of Wnt signaling pathway
  • Apoptotic cleavage of cellular proteins
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Deactivation of the beta-catenin transactivating complex
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • APC truncation mutants are not K63 polyubiquitinated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Ovarian tumor domain proteases
  • Cancer of the anal canal
  • Familial adenomatous polyposis
  • Gastric cancer
  • Esophageal cancer
  • Gallbladder cancer
Novel APC2 APC regulator of Wnt signaling pathway 2
  • Colorectal cancer
Novel APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1-dependent IKK and NF-kappa-B activation
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Gantenerumab
  • Aducanumab
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Lecanemab
  • Alzheimer's disease (AD)
Novel AR androgen receptor
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Ub-specific processing proteases
  • RUNX2 regulates osteoblast differentiation
  • RUNX2 regulates osteoblast differentiation
  • Diethylstilbestrol
  • Levonorgestrel
  • Progesterone
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Fluphenazine
  • Testosterone
  • Mitotane
  • Estrone
  • Nilutamide
  • Tamoxifen
  • Norethisterone
  • Drostanolone
  • Norgestimate
  • Nandrolone phenpropionate
  • Ketoconazole
  • Acetophenazine
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone propionate
  • Oxybenzone
  • 1-Testosterone
  • Boldenone
  • Calusterone
  • Periciazine
  • Prasterone
  • Flufenamic acid
  • Stanolone
  • (R)-Bicalutamide
  • Metribolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone acetate
  • LGD2941
  • Dimethylcurcumin
  • Oxymetholone
  • Methyltestosterone
  • Norelgestromin
  • Stanozolol
  • Tetrahydrogestrinone
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • BMS-564929
  • S-23
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • Andarine
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • LGD-2226
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Triclosan
  • Nandrolone decanoate
  • Ulipristal
  • Enzalutamide
  • Eugenol
  • Dienogest
  • Norethynodrel
  • Norgestrel
  • Homosalate
  • Enzacamene
  • Luprostiol
  • Mibolerone
  • Phenothiazine
  • Gestrinone
  • Apalutamide
  • Clascoterone
  • Darolutamide
  • Esculin
  • Ligandrol
  • Testosterone cypionate
  • Testosterone enanthate
  • Testosterone undecanoate
  • Stanolone acetate
  • Segesterone acetate
  • Boldenone undecylenate
  • Echinacoside
  • Ketodarolutamide
  • Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
  • 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism
  • Prostate cancer
  • 46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS)
Novel ARFGEF1 ARF guanine nucleotide exchange factor 1
Novel ARHGAP32 Rho GTPase activating protein 32
  • RHOA GTPase cycle
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOQ GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RAC3 GTPase cycle
  • RHOF GTPase cycle
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
Novel ARHGEF4 Rho guanine nucleotide exchange factor 4
  • NRAGE signals death through JNK
  • G alpha (12/13) signalling events
  • RHOA GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
Novel ASGR2 asialoglycoprotein receptor 2
  • Asparagine N-linked glycosylation
  • Antihemophilic factor, human recombinant
  • Lonoctocog alfa
  • Moroctocog alfa
Novel ASH2L ASH2 like, histone lysine methyltransferase complex subunit
  • Formation of the beta-catenin:TCF transactivating complex
  • PKMTs methylate histone lysines
  • Deactivation of the beta-catenin transactivating complex
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • Formation of WDR5-containing histone-modifying complexes
  • Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Regulation of PD-L1(CD274) transcription
  • Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome
Novel AXIN1 axin 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Degradation of AXIN
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Ub-specific processing proteases
  • RUNX1 regulates estrogen receptor mediated transcription
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Estrogen-dependent gene expression
  • 1,4-Dithiothreitol
  • Caudal duplication anomaly
  • Hepatocellular carcinoma
Novel AXIN2 axin 2
  • TCF dependent signaling in response to WNT
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Degradation of AXIN
  • Ub-specific processing proteases
  • Oligodontia-colorectal cancer syndrome
  • Tooth agenesis; Hypodontia
Novel BCL3 BCL3 transcription coactivator
Novel BCL6 BCL6 transcription repressor
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • FOXO-mediated transcription of cell death genes
  • Hairy-cell leukemia
Novel BCL9 BCL9 transcription coactivator
  • Formation of the beta-catenin:TCF transactivating complex
  • Deactivation of the beta-catenin transactivating complex
Novel BCL9L BCL9 like
  • Formation of the beta-catenin:TCF transactivating complex
  • Deactivation of the beta-catenin transactivating complex
Novel BOC BOC cell adhesion associated, oncogene regulated
  • Ligand-receptor interactions
  • Activation of SMO

Page 1 out of 22 pages